MoonLake Immunotherapeutics SEC filings MLTX
MoonLake Immunotherapeutics has 331 filings in SEC EDGAR's recent list, going back to Aug 28, 2020. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 25, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 22, 2026 | Jun 21, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 9, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 1, 2026 | May 22, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2026 | May 10, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Officer or director change, Regulation FD disclosure, Other events
|
Feb 23, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Material agreement
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Other events
|
Sep 29, 2025 | Sep 29, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 29, 2025 | Apr 29, 2025 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Apr 3, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2025 | Feb 26, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 18, 2024 | Dec 12, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2024 | Sep 11, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 10, 2024 | Jun 10, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 11, 2024 | Mar 10, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 26, 2024 | Feb 26, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2023 | Nov 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 6, 2023 | Nov 5, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2023 | Oct 15, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 1, 2023 | Aug 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 29, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2023 | Jun 26, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Officer or director change
|
May 19, 2023 | May 15, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 19, 2023 | Apr 19, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2023 | Mar 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Auditor change
|
Jun 17, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 7, 2022 | Jun 7, 2022 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
May 16, 2022 | Apr 5, 2022 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Apr 11, 2022 | Apr 5, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Mar 31, 2022 | Mar 31, 2022 |
| 8-K |
Current report
New debt
|
Mar 24, 2022 | Mar 21, 2022 |
| 8-K |
Current report
Material agreement
|
Feb 25, 2022 | Feb 20, 2022 |
| 8-K |
Current report
Restatement
|
Dec 3, 2021 | Nov 30, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 4, 2021 | Oct 4, 2021 |
| 8-K |
Current report
Officer or director change
|
May 3, 2021 | Apr 27, 2021 |
| 8-K |
Current report
Other events
|
Oct 28, 2020 | Oct 22, 2020 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Oct 22, 2020 | Oct 19, 2020 |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821586
- Former names
- Helix Acquisition Corp (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.